Company / Working Capital
ArriVent BioPharma, Inc. Working Capital History
FY2023-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$209.7M
FY2024
5-year range
$148.3M / $209.7M
FY2023-FY2024
Trend
+41.4%
vs FY2023
Sector context
#168 of 213
Health Care
What the data says
ArriVent BioPharma, Inc.'s working capital of $210M is lower than 79% of companies in the Health Care sector (FY2024).
Based on SEC 10-K filings.
$210M in FY2024.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 213This company $209.7M Sector average $934.6M
▼
-77.6% below sector average
Key checks
Key Insights
- In FY2024, working capital increased 41.4% year-over-year.
- Ranks #168 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 5.74 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $209.7M | +41.4% |
| FY2023 | $148.3M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026